Neurocrine Biosciences | NBIX - Marktkapitalisierung

Aktienkurs
128.89
Täglich Wechseln
-2.75 -2.09%
Monatlich
-0.50%
Jährlich
41.84%
Q2 Prognose
125.37




Marktkapitalisierung Veränderung Datum
AbbVie USD 403.83B 5.2B 2025-12
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Agios Pharmaceuticals USD 1.59B 745M 2025-12
ALKERMES USD 4.62B 333M 2025-12
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Biogen USD 25.82B 5.28B 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Cytokinetics USD 7.77B 1.19B 2025-12
Enanta Pharmaceuticals USD 122M 98M 2024-12
Exelixis USD 11.75B 959M 2025-12
Gilead Sciences USD 152.28B 14.55B 2025-12
Halozyme Therapeutics USD 7.91B 664M 2025-12
Incyte USD 19.39B 2.83B 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
Nektar Therapeutics USD 14.34B 13.48B 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Pfizer USD 141.57B 6.48B 2025-12
Prothena USD 514M 11M 2025-12
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Repligen USD 9.22B 1.7B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
Teva Pharmaceutical Industries USD 36.42B 14.06B 2025-12
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12